A link between HLA allelic variants and long-term results of surgery for gastric
tumors was established on the basis of a 10-years follow-up of 112
cancer patients (stage I-II--37.9, III-IV--62.1%; radical surgery--44.6%). HLA class I was studied in a lymphocytotoxic test; HLA class II--gene DRBI specificity using polymerase chain reaction of peripheral blood cell
DNA. The control group included healthy subjects living in the city of Novosibirsk (n = 341). High frequency of
antigens HLA-B41, -DR1, -DR7 (p < 0.01) co-occurred with
HLA-A2, -B12, -B13 and -B18 presence (p < 0.05) in
breast cancer patients. Clinical manifestations of
cancer were shown to develop in
HLA-A1, -B8, -B15, -DR3 and -DR5 carriers at early stages.
Tumor development at later stages (III-IV) was associated with
HLA-A2, -B12, -B17, -B35, -B41 and -DR7. A link was registered between lethality rate, on the one hand, and
HLA-A3, -B22, and, in particular, DR4, on the other, while remission of more than 7-years--with
HLA-A11, -B13, -B21 and -DR5. HLA-B22/DR3 phenotype involved worse prognosis in radically-treated patients whereas that of HLA-B8/DR3--a better one.